Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies

Anna Vardi, MD PhD, Elisavet Vlachonikola, Nikolaos Ioannou, PhD MSc, BSc, Fotis Psomopoulos, Konstantia Kotta, Despoina Papazoglou, BSc, Maria Kotouza, Evangelia Koravou, Chrysi Galigalidou, Katerina Gemenetzi, Kostas Pasentsis, Michalis Iskas, Niki Stavroyianni, Achilles Anagnostopoulos, Alan G. Ramsay, BSc, MSc, PhD, Kostas Stamatopoulos, MD PhD, Anastasia Hadzidimitriou, PhD

Blood (2018) 132 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2018-99-118006

Published: 2018

Journal Articles

A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Muhammad Asad Fraz, MD, Ali Younas Khan, MD, Sharoon Samuel, MBBS, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Muhammad Jahanzeb Khalil, MD, Muhammad Yasir, MD, Saher Nasir Amin, MD, Ahmad Safdar, Abdul Rafae, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5635.

https://doi.org/10.1182/blood-2018-99-115922

Published: 2018

Journal Articles

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Parayath Neha, Mansoor Amiji, Nikhil Munshi, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2018-99-117292

Published: 2018

Journal Articles

Phase II Trial of a Peptide Vaccine, Ocv-501 in Elderly Patients with Acute Myeloid Leukemia

Masaki Yamaguchi, MD PhD, Naoki Takezako, MD PhD, Toru Kiguchi, MD PhD, Shuichi Miyawaki, MD PhD, Yuji Heike, MD PhD, Kaori Mitsuki, Takahiro Yoshida, PhD, Ei Leen Liew, PhD MS, Tomoki Naoe, MD PhD

Blood (2018) 132 (Supplement 1): 29.

https://doi.org/10.1182/blood-2018-99-110013

Published: 2018

Journal Articles

Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma

Selma Bekri, PhD, Reunet Rodney-Sandy, BS, Diana Gruenstein, BS, Bjarne Bogen, MD PhD, Daniel Levey, PhD, Hearn Jay Cho, MD

Blood (2018) 132 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2018-99-117129

Published: 2018

Journal Articles

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Selma Bekri, PhD, Mohamed Uduman, PhD, Diana Gruenstein, BS, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Reunet Rodney-Sandy, BS, Bjarne Bogen, MD PhD, Jennifer Buell, PhD, Robert Stein, MD PhD, Kaitlin Doherty, Mark Findeis, PhD, Benjamin Morin, PhD, Bishnu Joshi, PhD, Antoine Tanne, PhD, John Castle, PhD, Daniel Levey, PhD, Hearn Jay Cho, MD PhD

Blood (2017) 130 (Supplement 1): 1868.

https://doi.org/10.1182/blood.V130.Suppl_1.1868.1868

Published: 2017

Journal Articles

Characterizing the Mechanism of NE and P3 Cross-Presentation in B Cell-Acute Lymphoblastic Leukemia

Selena Carmona, MS, Celine Kerros, PhD, Alexander Perakis, Anne Philip, Pariya Sukhumalchandra, Anna Sergeeva, PhD, Lisa St. John, Mao Zhang, MPH, Na Qiao, Elizabeth Mittendorf, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD

Blood (2017) 130 (Supplement 1): 3596.

https://doi.org/10.1182/blood.V130.Suppl_1.3596.3596

Published: 2017

Journal Articles

Definition and Characterization of a Peptide Warehouse for the Patient-Individualized Peptide Vaccination Study (iVAC-L-CLL01) after First Line Therapy of CLL

Tatjana Bilich, Annika Nelde, Daniel Johannes Kowalewski, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanovic, Helmut R. Salih, MD, Juliane Sarah Walz

Blood (2017) 130 (Supplement 1): 5346.

https://doi.org/10.1182/blood.V130.Suppl_1.5346.5346

Published: 2017

Journal Articles

Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS

Blood (2017) 130 (18): 1985–1994.

https://doi.org/10.1182/blood-2017-06-791202

Published: 2017

Includes: Supplemental data

Journal Articles

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Hongtao Liu, MD PhD, Yuanyuan Zha, PhD, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, PhD, Yusuke Nakamura, MD, Richard A. Larson, MD, Andres M Salazar, Olatoyosi Odenike, MD, Thomas Gajewski, MD PhD, Wendy Stock, MD

Blood (2016) 128 (22): 3984.

https://doi.org/10.1182/blood.V128.22.3984.3984

Published: 2016

Journal Articles

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

Shigesaburo Miyakoshi, MD PhD, Kensuke Usuki, MD PhD, Itaru Matsumura, MD PhD, Yasunori Ueda, MD PhD, Hiromi Iwasaki, MD PhD, Toshihiro Miyamoto, MD PhD, Makoto Origuchi, Shuzo Tagashira, Ichiro Naoi, Tomoki Naoe, MD PhD, Masahiro Kizaki, MD PhD, Yuji Heike, MD PhD, Koichi Akashi, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2016) 128 (22): 4335.

https://doi.org/10.1182/blood.V128.22.4335.4335

Published: 2016

Journal Articles

DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1

Masashi Goto, PhD, Megumi Nakamura, PhD, Natsuko Suginobe, MS, Hideo Takasu, PhD, Yosuke Takanashi, MS, Hitoshi Ban, PhD, Chiang J Li, MD

Blood (2016) 128 (22): 4715.

https://doi.org/10.1182/blood.V128.22.4715.4715

Published: 2016

Journal Articles

Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)

Ajay K Nooka, MD MPH, Michael Wang, MD, Andrew J. Yee, MD, Sheeba K. Thomas, MD, Elizabeth K. O'Donnell, MD, Jatin J. Shah, MD, Jonathan L. Kaufman, MD, Doris Peterkin, MBA, Sagar Lonial, MD FACP, Paul G. Richardson, MD, Noopur Raje, MD

Blood (2016) 128 (22): 2124.

https://doi.org/10.1182/blood.V128.22.2124.2124

Published: 2016

Journal Articles

A New Peptide Vaccine Ocv-501, Phase 1 Study in Patients with Acute Myeloid Leukemia and In Vitro Pharmacology

Tohru Sakura, MD, Yukio Kobayashi, MD PhD, Shuichi Miyawaki, MD PhD, Kazuyuki Toga, MS, Shinji Sogo, PhD, Yuji Heike, MD PhD

Blood (2016) 128 (22): 1643.

https://doi.org/10.1182/blood.V128.22.1643.1643

Published: 2016

Journal Articles

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Takahiro Suzuki, MD PhD, Yasunori Ueda, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Keiya Ozawa, MD PhD, Shigesaburo Miyakoshi, MDPhD, Tomoki Naoe, MD PhD, Makoto Murata, MD PhD, Masahiro Kizaki, MD PhD, Naokuni Uike, MD, Yasunobu Abe, MD PhD, Michihiro Hidaka, MD PhD, Shuzo Tagashira, Satoru Tsuchiya, Kazuma Ohyashiki, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2015) 126 (23): 2868.

https://doi.org/10.1182/blood.V126.23.2868.2868

Published: 2015

Journal Articles

Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy

Daniel Johannes Kowalewski, Simon D. Walz, Linus Backert, Heiko Schuster, Susanne M. Rittig, MD, Katja C. Weisel, Helmut R Salih, MD, Lothar Kanz, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S Stickel, MD

Blood (2015) 126 (23): 3001.

https://doi.org/10.1182/blood.V126.23.3001.3001

Published: 2015

Journal Articles

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Isao Tawara, MD PhD, Masahiro Masuya, MD PhD, Shinichi Kageyama, MD PhD, Tetsuya Nishida, MD PhD, Seitaro Terakura, MD PhD, Makoto Murata, MD PhD, Hiroshi Fujiwara, MD PhD, Yoshiki Akatsuka, MD PhD, Hiroaki Ikeda, MD PhD, Yoshihiro Miyahara, MD PhD, Daisuke Tomura, PhD, Ikuei Nukaya, PhD, Kazutoh Takesako, PhD, Nobuhiko Emi, MDPhD, Masaki Yasukawa, MD PhD, Naoyuki Katayama, MD PhD, Hiroshi Shiku, MD PhD

Blood (2015) 126 (23): 97.

https://doi.org/10.1182/blood.V126.23.97.97

Published: 2015

Journal Articles

Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type

Sebastian P. Haen, MD, Daniel Johannes Kowalewski, Stefan Stevanovic, PhD, Linus Backert, Florian Dengler, Daniel Backes, Stefan Beckert, Wagner Silvia, Ingmar Koenigsrainer, Hans-Georg Kopp, MD, Oliver Kohlbacher, Alfred Koenigsrainer, MD, Lothar Kanz, MD, Hans-Georg Rammensee, PhD, Markus W. Loeffler, MD

Blood (2015) 126 (23): 1027.

https://doi.org/10.1182/blood.V126.23.1027.1027

Published: 2015

Journal Articles

Long Term Update on Phase I/II Trial with Immucin Anti-MUC1 Signal Peptide Vaccine for Multiple Myeloma Patients with Residual Disease or Progression

Lior Carmon, PhD, Irit Avivi, Riva Kovjazin, Lillian Dary, Michael Y Shapira, MD

Blood (2014) 124 (21): 4768.

https://doi.org/10.1182/blood.V124.21.4768.4768

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies

A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Phase II Trial of a Peptide Vaccine, Ocv-501 in Elderly Patients with Acute Myeloid Leukemia

Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Characterizing the Mechanism of NE and P3 Cross-Presentation in B Cell-Acute Lymphoblastic Leukemia

Definition and Characterization of a Peptide Warehouse for the Patient-Individualized Peptide Vaccination Study (iVAC-L-CLL01) after First Line Therapy of CLL

Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1

Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)

A New Peptide Vaccine Ocv-501, Phase 1 Study in Patients with Acute Myeloid Leukemia and In Vitro Pharmacology

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type

Long Term Update on Phase I/II Trial with Immucin Anti-MUC1 Signal Peptide Vaccine for Multiple Myeloma Patients with Residual Disease or Progression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only